|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
IL-17A (P < .039) and TNFα (P < .008) were expressed at significantly higher levels in psoriasis or pustular-like reactions (PPR) compared to eczematous-like reactions (ELR).
|
29023827 |
2018 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In case of a severe course of psoriasis and moderate-to-severe disease in which traditional systemic treatments are ineffective or contraindicated, TNF-α inhibitors (iTNF-α) are used.
|
30288872 |
2019 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TNF-α levels in patients with ichthyosis were increased only in those with Netherton syndrome but were much lower than in patients with psoriasis and those with AD.
|
27554821 |
2017 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Analysis of gene expression confirmed dysregulation in all expected functional categories, such as IFN signaling and keratinocyte differentiation, and allowed molecular fingerprinting of a previously characterized dendritic cell subset associated with psoriasis tumor necrosis factor alpha (TNF-alpha)- and inducible nitric oxide synthase (iNOS)-producing CD11b(INT) DC (Tip-DC).
|
17637826 |
2008 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The clinical success of biologics that inhibit TNF (Tumor Necrosis Factor) in inflammatory bowel diseases (IBD), psoriasis and rheumatoid arthritis (RA) has clearly established a pathogenic role for this cytokine in these inflammatory disorders.
|
31457011 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
TNF-α plays a crucial role in psoriasis; therefore, TNF inhibition has become a gold standard for the treatment of psoriasis.
|
25384035 |
2014 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our aim was to evaluate the effect of DNA variants at the "TNFα pathway" that could affect the risk of developing Psoriasis or the response to biological therapies among these patients.
|
25537528 |
2015 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We aimed to determine whether Cw6 and the genetic polymorphism of the CDSN gene, POU5F1 gene, MICA gene and the gene for TNF-alpha promoter region were associated with an increased risk of psoriasis in Chinese patients.
|
12653732 |
2003 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor (TNF) α which releases from keratinocytes activates dendritic cells in the early stages of complex pathogenesis of psoriasis.
|
30972872 |
2019 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Biologics licensed for psoriasis include the TNFα inhibitors (infliximab, adalimumab, etanercept), the interleukin (IL)-12/23 monoclonal antibody (ustekinumab), and IL-17 inhibitor (secukinumab, ixekizumab).
|
29299984 |
2017 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
CTD_human |
Possible association of psoriasis and reduced bone mineral density due to increased TNF-alpha and IL-6 concentrations.
|
16844318 |
2006 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Current clinical paradigms for the treatment of psoriasis have evolved to include targeted biologic therapies, starting with tumour necrosis factor-alpha (TNF-α) inhibitors and later, agents targeting interleukin (IL)-12/23 and IL-17.
|
29438576 |
2018 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The small molecule rhodomyrtone suppresses TNF-α and IL-17A-induced keratinocyte inflammatory responses: A potential new therapeutic for psoriasis.
|
30321197 |
2018 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Longer and larger studies are needed to explain why tumor necrosis factor-α blockade appears to reduce cardiovascular events in patients with severe psoriasis.
|
28735613 |
2017 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
To analyze globally the genomic effects of TNF inhibition in patients with psoriasis, and to compare genomic profiles of patients who responded or did not respond to treatment.
|
19895991 |
2009 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Currently, there is no cure for PsO; however, the introduction of biologic therapies has revolutionized the clinical management of patients with PsO by expanding treatment options to include multiple therapies with different mechanisms of action targeting cytokines, including tumor necrosis factor inhibitors (TNFis), interleukin (IL)-17A inhibitors, an IL-12/23 inhibitor, and IL-23 inhibitors.
|
31424708 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Methotrexate and tumor necrosis factor inhibitors are favored in European League Against Rheumatism guidelines, whereas other conventional synthetic disease-modifying antirheumatic drugs and biologics are equally positioned in Group for Research and Assessment of Psoriasis and PsA recommendations.
|
29035933 |
2018 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although IL-17A and TNFα are effective therapeutic targets in psoriasis, IL-36 has recently emerged as a proinflammatory cytokine.
|
30224457 |
2018 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pituitary tumor transforming gene 1 induces tumor necrosis factor-α production from keratinocytes: implication for involvement in the pathophysiology of psoriasis.
|
23677169 |
2013 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IL-36γ expression is enhanced by tumor necrosis factor-α and IL-17A, having a strong association with psoriasis.
|
29314201 |
2018 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this study, we report association of response of psoriasis to TNF blockers with two TNFAIP3 single-nucleotide polymorphisms (rs2230926 in exon 7 and rs610604 in intron 3) and their haplotypes.
|
22113471 |
2012 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inhibitors of key mediators in the Th1 pathway such as TNFα are successful therapeutic targets for the treatment of various inflammatory conditions such as psoriasis, psoriatic arthritis, rheumatoid arthritis and inflammatory bowel disease.
|
27571340 |
2017 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PCR Real time Mismatch Amplification Mutation Assay (MAMA Real Time PCR) for evaluation of TNF-α promoter gene polymorphism -308 G/A in patients with psoriasis.
|
26584427 |
2016 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Activation of keratinocyte protein kinase C zeta in psoriasis plaques.
|
18385757 |
2008 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings confirm the importance of TNF-α in psoriasis pathogenesis and a positive correlation with lesions severity.
|
31384319 |
2019 |